GRAIL and athenahealth Team Up to Offer Healthcare Providers Streamlined Ordering of GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Test
GRAIL (NASDAQ: GRAL) has announced a strategic partnership with athenahealth to integrate its Galleri® multi-cancer early detection (MCED) test into athenaCoordinator Core. The integration will enable over 160,000 U.S. clinicians on athenahealth's network to seamlessly order the Galleri test through their electronic health record (EHR) system.
The Galleri test, which detects cancer through DNA fragments in blood samples, can screen for multiple deadly cancers before symptoms appear and identify the cancer's origin. The test is prescription-only and recommended for adults with elevated cancer risk, particularly those 50 or older, complementing existing cancer screening methods.
This partnership aims to streamline the ordering process, reduce administrative burden, and increase patient access to early cancer detection services.GRAIL (NASDAQ: GRAL) ha annunciato una partnership strategica con athenahealth per integrare il suo test Galleri® per la rilevazione precoce di più tipi di cancro (MCED) all'interno di athenaCoordinator Core. Questa integrazione permetterà a oltre 160.000 clinici statunitensi della rete di athenahealth di ordinare facilmente il test Galleri tramite il loro sistema di cartelle cliniche elettroniche (EHR).
Il test Galleri, che rileva il cancro attraverso frammenti di DNA presenti nei campioni di sangue, può individuare diversi tipi di tumori letali prima della comparsa dei sintomi e identificare l'origine del cancro. Il test è disponibile solo su prescrizione ed è raccomandato per adulti con rischio elevato di cancro, in particolare per chi ha 50 anni o più, integrando i metodi di screening oncologico già esistenti.
Questa collaborazione mira a semplificare il processo di ordinazione, ridurre il carico amministrativo e aumentare l'accesso dei pazienti ai servizi di diagnosi precoce del cancro.
GRAIL (NASDAQ: GRAL) ha anunciado una alianza estratégica con athenahealth para integrar su prueba Galleri® de detección temprana de múltiples cánceres (MCED) en athenaCoordinator Core. Esta integración permitirá que más de 160,000 médicos en EE.UU. dentro de la red de athenahealth puedan solicitar la prueba Galleri de forma sencilla a través de su sistema de registros electrónicos de salud (EHR).
La prueba Galleri, que detecta cáncer mediante fragmentos de ADN en muestras de sangre, puede detectar múltiples tipos de cáncer mortales antes de que aparezcan los síntomas e identificar el origen del cáncer. La prueba solo está disponible con receta y se recomienda para adultos con riesgo elevado de cáncer, especialmente mayores de 50 años, complementando los métodos de detección existentes.
Esta colaboración busca facilitar el proceso de solicitud, reducir la carga administrativa y aumentar el acceso de los pacientes a servicios de detección temprana del cáncer.
GRAIL (NASDAQ: GRAL)은 athenahealth와 전략적 파트너십을 체결하여 자사의 Galleri® 다중 암 조기 발견(MCED) 검사를 athenaCoordinator Core에 통합한다고 발표했습니다. 이 통합을 통해 athenahealth 네트워크에 속한 16만 명 이상의 미국 임상 의사가 전자의무기록(EHR) 시스템을 통해 Galleri 검사를 원활하게 주문할 수 있게 됩니다.
Galleri 검사는 혈액 샘플 내 DNA 조각을 통해 암을 감지하며, 증상이 나타나기 전 여러 치명적인 암을 선별하고 암의 기원을 파악할 수 있습니다. 이 검사는 처방전이 있어야 하며, 특히 50세 이상 고위험 성인을 대상으로 기존 암 검진 방법을 보완하는 용도로 권장됩니다.
이번 파트너십은 주문 과정을 간소화하고 행정 부담을 줄이며 환자들이 조기 암 발견 서비스를 더 쉽게 이용할 수 있도록 하는 것을 목표로 합니다.
GRAIL (NASDAQ : GRAL) a annoncé un partenariat stratégique avec athenahealth pour intégrer son test Galleri® de détection précoce multi-cancers (MCED) dans athenaCoordinator Core. Cette intégration permettra à plus de 160 000 cliniciens américains du réseau d'athenahealth de commander facilement le test Galleri via leur système de dossier médical électronique (DME).
Le test Galleri, qui détecte le cancer à partir de fragments d'ADN dans des échantillons sanguins, peut dépister plusieurs cancers mortels avant l'apparition des symptômes et identifier l'origine du cancer. Ce test est disponible uniquement sur ordonnance et recommandé aux adultes présentant un risque accru de cancer, notamment ceux âgés de 50 ans et plus, en complément des méthodes de dépistage existantes.
Ce partenariat vise à simplifier le processus de commande, réduire la charge administrative et augmenter l'accès des patients aux services de détection précoce du cancer.
GRAIL (NASDAQ: GRAL) hat eine strategische Partnerschaft mit athenahealth bekannt gegeben, um seinen Galleri® Multi-Krebs-Früherkennungstest (MCED) in athenaCoordinator Core zu integrieren. Die Integration ermöglicht es über 160.000 US-amerikanischen Ärzten im Netzwerk von athenahealth, den Galleri-Test nahtlos über ihr elektronisches Gesundheitsakten-System (EHR) zu bestellen.
Der Galleri-Test erkennt Krebs durch DNA-Fragmente in Blutproben, kann mehrere tödliche Krebsarten vor dem Auftreten von Symptomen erkennen und die Herkunft des Krebses bestimmen. Der Test ist verschreibungspflichtig und wird für Erwachsene mit erhöhtem Krebsrisiko, insbesondere ab 50 Jahren, empfohlen und ergänzt bestehende Krebsfrüherkennungsmethoden.
Die Partnerschaft zielt darauf ab, den Bestellprozess zu vereinfachen, die administrative Belastung zu reduzieren und den Patienten den Zugang zu Früherkennungsdiensten für Krebs zu erleichtern.
- Integration with athenahealth's network provides access to over 160,000 U.S. clinicians, significantly expanding GRAIL's market reach
- Streamlined ordering process through EHR integration reduces administrative burden and improves efficiency
- Automatic test results integration into patient charts enhances workflow efficiency
- Test remains prescription-only, limiting widespread adoption
- Limited to adults with elevated cancer risk, primarily those 50 or older
Insights
GRAIL's athenahealth integration creates significant distribution opportunity, potentially accelerating adoption of their cancer screening technology across 160,000+ clinicians.
This partnership represents a substantial distribution expansion for GRAIL's Galleri test. Integration with athenahealth's EHR platform offers access to over 160,000 U.S. clinicians, dramatically reducing friction in test ordering workflows. The technical integration into athenaCoordinator Core will allow physicians to order the test directly within their existing EHR system rather than through separate portals or paperwork.
From a clinical perspective, the Galleri test addresses a critical gap in cancer screening. While we have established screening protocols for certain cancers (mammography, colonoscopy, PSA testing), many deadly cancers lack early detection methods. The Galleri test's ability to detect cancer signals across multiple cancer types with a simple blood draw represents a paradigm shift in preventive oncology.
The workflow improvements are particularly noteworthy: automatic test results appearing in patient charts eliminates manual entry, reducing administrative burden and potential transcription errors. For practices concerned with operational efficiency, this streamlining addresses a key adoption barrier.
The target demographic for Galleri – adults 50+ with elevated cancer risk – aligns perfectly with populations most actively managed within primary care settings, where athenahealth has strong market penetration. This partnership creates a seamless pathway for physicians to incorporate cutting-edge cancer detection into routine preventive care workflows, potentially allowing earlier interventions when treatment outcomes are typically more favorable and less costly.
Integration with athenaCoordinator Core will allow over 160,000
"Cancer remains a public health crisis. There is a clear need to transform the way we screen for cancer while still asymptomatic, when it can be more easily treated," said Josh Ofman, MD, MSHS, president at GRAIL. "Integrating with athenaCoordinator Core will help simplify the Galleri test ordering process as part of routine exams and help increase patient access to multi-cancer early detection to screen for some of the deadliest cancers before they become symptomatic."
Cancers growing in the body shed DNA into the bloodstream. These DNA fragments act like a unique "fingerprint" of cancer. With a single blood draw, the Galleri test screens for the "fingerprint" of many of the deadliest cancers before they become symptomatic, including those with no recommended screening tests today. It can also provide doctors with information on the cancer's origin to help predict the tissue type or organ associated with the cancer signal. The Galleri test is prescription only, recommended for adults with an elevated risk for cancer, such as those age 50 or older, and is to be used in addition to recommended cancer screenings.
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in
For more information, visit grail.com.
About Galleri®
The Galleri multi-cancer early detection test is a proactive tool to screen for cancer. With a simple blood draw, the Galleri test can identify DNA shed by cancer cells, which can act as a unique "fingerprint" of cancer, to help screen for some of the deadliest cancers that don't have recommended screening today, such as pancreatic, esophageal, ovarian, liver, and others.* The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer, giving healthcare providers a roadmap of where to explore further. The Galleri test requires a prescription from a licensed healthcare provider and should be used in addition to recommended cancer screenings such as mammography, colonoscopy, prostate-specific antigen (PSA) test, or cervical cancer screening. The Galleri test is recommended for adults with an elevated risk for cancer, such as those aged 50 or older.
For more information, visit galleri.com.
Sensitivity in study participants with –
Pancreas cancer:
Important Galleri Safety Information
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those age 50 or older. The test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. The Galleri test is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of the test is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.
Results should be interpreted by a healthcare provider in the context of medical history, clinical signs, and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer.
If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False positive (a cancer signal detected when cancer is not present) and false negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.
Laboratory/Test Information
The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed — and its performance characteristics were determined — by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.
Forward Looking Statements
This press release contains forward-looking statements. In some cases, you can identify these statements by forward-looking words such as "aim," "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "should," "would," or "will," the negative of these terms, and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties, and assumptions about us, may include expectations about or projections ease of ordering Galleri, potential increases in patient access, clinical impact, technology, clinical and real world studies, regulatory compliance, potential market opportunity, anticipated growth strategies, and other topics.
These statements are only predictions based on our current expectations and projections about future events and trends. There are important factors that could cause our actual results, level of activity, performance, or achievements to differ materially and adversely from those expressed or implied by the forward-looking statements, including those factors and numerous associated risks discussed under the section entitled "Risk Factors" in our Annual Report on Form 10-Q for the period ended March 31, 2025 and our Form 10-K for the period ended December 31, 2024 (the "Form 10-K"). Moreover, we operate in a dynamic and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results, level of activity, performance, or achievements to differ materially and adversely from those contained in any forward-looking statements we may make.
Forward-looking statements relate to the future and, accordingly, are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Although we believe the expectations and projections expressed or implied by the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Except to the extent required by law, we undertake no obligation to update any of these forward-looking statements after the date of this press release to conform our prior statements to actual results or revised expectations or to reflect new information or the occurrence of unanticipated events.
View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-and-athenahealth-team-up-to-offer-healthcare-providers-streamlined-ordering-of-grails-galleri-multi-cancer-early-detection-mced-test-302452612.html
SOURCE GRAIL, Inc.
FAQ
What is the partnership between GRAIL and athenahealth for the Galleri test?
How does GRAL's Galleri cancer detection test work?
Who is eligible for GRAIL's Galleri cancer screening test?
What are the benefits of GRAL's athenahealth integration for healthcare providers?
